- Reports: ESI may start 'price war' over new hepatitis C drugs
- FDA approves J&J's Olysio for hepatitis C
- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
- Newly approved hepatitis C treatment by Gilead Sciences said to offer major advance in treatment
- Could ESI block Sovaldi from its formulary?
NEW YORK The Hart-Scott-Rodino waiting period for Bristol-Myers Squibb’s acquisition of Seattle-based biotech company ZymoGenetics has expired, enabling Bristol’s acquisition to go through, the drug maker said Tuesday.
The drug maker announced the deal to acquire ZymoGenetics for $885 million, or $9.75 per share, earlier this month.
The buyout gives Bristol ownership of Recothrom, a drug used to control bleeding during surgical procedures; an investigative treatment for hepatitis C called pegylated-interferon lambda; and an investigative treatment for melanoma called interleukin-21, or IL-21.